CERo Therapeutics (CERO) Competitors $5.40 -0.10 (-1.82%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.40 +0.00 (+0.09%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CERO vs. MURA, XCUR, JATT, RNXT, SCYX, HYPD, MDCX, THAR, DYAI, and RNTXShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Mural Oncology (MURA), Exicure (XCUR), JATT Acquisition (JATT), RenovoRx (RNXT), SCYNEXIS (SCYX), Hyperion DeFi (HYPD), Medicus Pharma (MDCX), Tharimmune (THAR), Dyadic International (DYAI), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Its Competitors Mural Oncology Exicure JATT Acquisition RenovoRx SCYNEXIS Hyperion DeFi Medicus Pharma Tharimmune Dyadic International Rein Therapeutics CERo Therapeutics (NASDAQ:CERO) and Mural Oncology (NASDAQ:MURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Does the media favor CERO or MURA? In the previous week, CERo Therapeutics had 4 more articles in the media than Mural Oncology. MarketBeat recorded 6 mentions for CERo Therapeutics and 2 mentions for Mural Oncology. Mural Oncology's average media sentiment score of 0.45 beat CERo Therapeutics' score of 0.37 indicating that Mural Oncology is being referred to more favorably in the news media. Company Overall Sentiment CERo Therapeutics Neutral Mural Oncology Neutral Which has stronger valuation and earnings, CERO or MURA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCERo TherapeuticsN/AN/A-$8.30MN/AN/AMural OncologyN/AN/A-$128.51M-$8.59-0.24 Do institutionals and insiders have more ownership in CERO or MURA? 29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 80.2% of Mural Oncology shares are held by institutional investors. 12.7% of CERo Therapeutics shares are held by insiders. Comparatively, 2.2% of Mural Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend CERO or MURA? CERo Therapeutics presently has a consensus price target of $45.00, indicating a potential upside of 733.33%. Mural Oncology has a consensus price target of $12.00, indicating a potential upside of 476.92%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe CERo Therapeutics is more favorable than Mural Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CERO or MURA more profitable? CERo Therapeutics' return on equity of 0.00% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets CERo TherapeuticsN/A N/A -209.40% Mural Oncology N/A -107.76%-87.57% Which has more risk and volatility, CERO or MURA? CERo Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Mural Oncology has a beta of 2.99, meaning that its share price is 199% more volatile than the S&P 500. SummaryCERo Therapeutics beats Mural Oncology on 7 of the 11 factors compared between the two stocks. Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CERO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.63M$2.60B$5.86B$10.14BDividend YieldN/A56.52%5.68%4.60%P/E RatioN/A23.8575.0625.97Price / SalesN/A529.66514.97181.20Price / CashN/A171.1637.5660.44Price / Book-0.135.3712.156.29Net Income-$8.30M$32.95M$3.29B$270.96M7 Day Performance-8.78%1.28%0.75%3.87%1 Month Performance-34.78%6.09%4.82%4.88%1 Year Performance-97.10%-2.15%60.59%26.12% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo Therapeutics3.5667 of 5 stars$5.40-1.8%$45.00+733.3%-96.9%$6.63MN/A0.008MURAMural Oncology2.5563 of 5 stars$2.08+1.0%$12.00+476.9%-34.0%$35.69MN/A-0.24119Short Interest ↑XCURExicure1.3774 of 5 stars$5.47-2.5%N/A+153.6%$35.44M$500K-1.4150Positive NewsGap UpJATTJATT AcquisitionN/A$2.04-3.8%N/A-42.3%$35.19MN/A0.003News CoverageHigh Trading VolumeRNXTRenovoRx2.3517 of 5 stars$1.08+12.5%$7.50+594.4%+19.6%$35.18M$40K-2.846News CoverageShort Interest ↑Gap UpHigh Trading VolumeSCYXSCYNEXIS1.6353 of 5 stars$0.84+0.5%N/A-16.4%$34.86M$3.26M-2.0960Positive NewsGap UpHYPDHyperion DeFi0.4046 of 5 stars$5.93-2.8%$2.00-66.3%-65.5%$34.74M$60K-0.1040Gap UpMDCXMedicus Pharma1.8098 of 5 stars$2.08+7.2%$23.50+1,029.8%N/A$34.56MN/A-1.55N/ANews CoverageTHARTharimmune2.4617 of 5 stars$5.20-12.6%$17.00+226.9%+5.0%$33.86MN/A-0.852Short Interest ↑Gap UpDYAIDyadic International2.6033 of 5 stars$0.95+3.3%$6.00+530.5%-22.0%$33.34M$3.42M-5.017Short Interest ↑RNTXRein Therapeutics0.999 of 5 stars$1.35-2.9%N/AN/A$32.39MN/A0.009News CoveragePositive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies MURA Alternatives XCUR Alternatives JATT Alternatives RNXT Alternatives SCYX Alternatives HYPD Alternatives MDCX Alternatives THAR Alternatives DYAI Alternatives RNTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CERO) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERO Stock Alerts